NEOG vs PRME
NEOG: Neogen provides food and animal safety solutions including diagnostics, pathogen detection, and genomics products for food manufacturers and livestock producers. PRME: A biotechnology company developing next-generation gene editing therapies based on its proprietary Prime Editing platform to cure serious genetic diseases.
Side-by-side fundamentals
| Metric | NEOG | PRME | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $9.83 | $3.09 | |
| Market cap as of 2026-07-23 | $2.2B | $564M | |
| PEG as of 2026-07-23 | -0.14 | n/a | |
| Net margin as of 2026-07-23 | -69.9% | -4917.6% | NEOG higher |
| Gross margin as of 2026-07-23 | +45.2% | n/a | |
| Operating margin as of 2026-07-23 | -64.3% | -5121.8% | NEOG higher |
| ROE as of 2026-07-23 | -29.0% | -188.8% | NEOG higher |
| ROA as of 2026-07-23 | -18.0% | -61.0% | NEOG higher |
| Debt / equity as of 2026-07-23 | 0.38 | 0.00 | PRME lower |
| Revenue growth (YoY) as of 2026-07-23 | -3.9% | +4.9% | PRME higher |
| Revenue CAGR (3y) SEC XBRL | +19.3% | n/a | |
| Beta as of 2026-07-23 | 1.81 | 2.27 | |
| 1-year return as of 2026-07-22 close | +95.8% | -31.7% | NEOG higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.